A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Participants.

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Healthy Participants

In brief

The objective of this clinical study is to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of SV003 in healthy subjects.

Key facts

Study ID

NCT07469085

Run by

Shanghai Synvida Biotechnology Co.,Ltd.

People needed

60

Starts

2026-04-04

Expected to finish

2027-03-31

Last updated by the study team

2026-04-08

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body Mass Index (BMI): 18.5 ≤ Chinese participants ≤ 30 kg/m², 18.5 ≤ Caucasian participants ≤ 32 kg/m²; additionally, male participants must have a body weight ≥ 50 kg, and female participants ≥ 45 kg;
• Healthy status: No evidence of active or chronic diseases in participants;
• Ability to participate in the study, willingness to provide written informed consent, and compliance with study requirements.

You may not qualify if…

• Subjects with a history of chronic diseases or currently presenting with clinically significant systemic diseases;
• Subjects who have experienced a serious disease within 1 month prior to drug administration, or with any disease that may relapse immediately during or after the study;
• Subjects with designated examination results reaching a specified value;
• Subjects with abnormal laboratory test results deemed clinically significant by the investigator;
• Subjects positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or Treponema pallidum antibody;
• Subjects with a history of drug abuse within the past 2 years, or with a positive urine drug screen on Day -1;
• Subjects with a history of alcohol dependence within the past 2 years, or with a positive breath alcohol test result on Day -1;
• Subjects with an average daily cigarette consumption of ≥ 5 cigarettes within 3 months prior to screening;
• Subjects who have donated blood or lost blood ≥ 400 mL within 3 months prior to drug administration, or donated blood or lost blood ≥ 200 mL within 1 month, or with a history of blood product use;
• Subjects with an allergic constitution, or with a history of allergy to the study drug, drugs of the same class or excipients;
• Subjects who have participated in clinical studies of investigational drugs or medical devices within 3 months prior to drug administration;
• Female subjects with a positive pregnancy test during the screening period or on Day -1, or who are breastfeeding;
• Chinese female subjects who are postmenopausal or have an irregular menstrual cycle;
• Female subjects of childbearing potential, or male subjects whose female partners are of childbearing potential, who refuse to adopt reliable contraceptive measures during the study and for 6 months after the last drug administration;
• Any other factors that the investigator deems may render a subject unsuitable for study participation.

Where it is running

• Shanghai Xuhui Central Hospital — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.